ALINT.PA WACC - Weighted Average Cost of Capital
The WACC of Integragen SA (ALINT.PA) is 6.8%.
| Range | Selected | |
| Cost of equity | 6.0% - 9.2% | 7.6% |
| Tax rate | 17.2% - 22.5% | 19.85% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 5.6% - 8.1% | 6.8% |
| Category | Low | High |
| Long-term bond rate | 1.7% | 2.2% |
| Equity market risk premium | 5.2% | 6.2% |
| Adjusted beta | 0.82 | 1.06 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 6.0% | 9.2% |
| Tax rate | 17.2% | 22.5% |
| Debt/Equity ratio | 0.28 | 0.28 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 5.6% | 8.1% |
| Selected WACC | 6.8% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| ALINT.PA | Integragen SA | 0.28 | 0.31 | 0.26 |
| ABVX.PA | Abivax SA | 0.3 | 1.69 | 1.36 |
| ALCLS.PA | Cellectis SA | 0.81 | 0.91 | 0.55 |
| DBV.PA | DBV Technologies SA | 0.03 | 0.6 | 0.59 |
| IPH.PA | Innate Pharma SA | 0.48 | 0.95 | 0.68 |
| IVA.PA | Inventiva SA | 0.14 | 0.89 | 0.8 |
| NANO.PA | Nanobiotix SA | 0.31 | 1.53 | 1.22 |
| POXEL.PA | Poxel SA | 1.99 | -0.18 | -0.07 |
| VLA.PA | Valneva SE | 0.47 | 1.51 | 1.09 |
| Low | High | |
| Unlevered beta | 0.61 | 0.78 |
| Relevered beta | 0.73 | 1.09 |
| Adjusted relevered beta | 0.82 | 1.06 |
ALINT.PA's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ALINT.PA:
cost_of_equity (7.60%) = risk_free_rate (1.95%) + equity_risk_premium (5.70%) * adjusted_beta (0.82) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.